Menlo Park, California-based Acclarent is to ramp up commercialisation of its balloon catheter-based sinus treatment, Balloon Sinuplasty, after receiving $26m in new capital. The funds came from Acclarent's existing shareholders as well as new investor Johnson & Johnson. Part of the proceeds will also go towards advancing development of Acclarent's pipeline products and clinical studies.